Jump to content
RemedySpot.com

Re: NATAP: FDA Approves GARDASIL for Anal Cancer

Rate this topic


Recommended Posts

Posted

Does anyone know what this means for those of us who are (WAY)over 26, as relates to having insurance pay for it? I assume that would be considered "off label"--- Would most insurances pay for it, if it hasn't yet technically been demonstrated to be useful for people over the age of 26? My insurance pays for most vaccinations without a copay, but I expect this might be a reason why they'd not pay for it. Anyone with any insight about this sort of thing?>> > > Subject: NATAP: FDA Approves GARDASIL for Anal Cancer> > > > > > > > Dec. 22, 2010> > US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL®> > US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL®> > > > GARDASIL now Approved for Prevention of Anal Cancer and AIN> > > > WHITEHOUSE STATION, N.J., Dec. 22, 2010 - Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.> > > > "We are pleased that with this new indication for GARDASIL against HPV-related anal cancer and disease, both males and females can be protected against cancer, which further reinforces the importance of vaccinating both genders," said M. Haupt, M.D., MPH, executive director, Merck Research Laboratories. "GARDASIL is the only HPV vaccine available for use in both males and females, and the only one indicated to help prevent cervical, vaginal, vulvar and anal cancers and pre-cancers, as well as genital warts, caused by certain types of HPV."> > > > In the United States, an estimated 75 to 80 percent of males and females will be infected with HPV in their lifetime. For most, HPV will clear on its own. However, for those who don't clear certain types, HPV can cause cervical, vaginal and vulvar cancers in women and anal cancer and genital warts in men and women. There is no way to predict who will or won't clear the virus.> > > > GARDASIL helps protect against the four types of HPV, specifically types 6, 11, 16, and 18, that cause the most disease. It is estimated that HPV types 16 and 18 account for approximately 80 percent of anal cancers, 75 percent of cervical cancers, 70 percent of vaginal cancers and 40 to 50 percent of vulvar cancers. HPV types 6 and 11 cause approximately 90 percent of all genital warts cases.> > > > Anal cancer affects both men and women, with approximately 60 percent of cases occurring in women. According to the American Cancer Society, it is estimated that approximately 2,000 men and more than 3,000 women will have been diagnosed with anal cancer in 2010. There is no standardized screening recommended for the general population for anal cancer and many people are diagnosed when the disease is more advanced.> > > > GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] was approved in the United States in 2006 and is also indicated for use in girls and young women 9 through 26 years of age for the prevention of cervical, vulvar and vaginal cancers caused by HPV types 16 and 18; genital warts (condylomata acuminata) caused by HPV types 6 and 11; and precancerous or dysplastic lesions caused by HPV types 6, 11, 16 and 18. GARDASIL is also approved in the U.S. for use in boys and men ages 9 through 26 years of age for the prevention of genital warts caused by HPV types 6 and 11.> > > > Important information about GARDASIL> > GARDASIL does not eliminate the necessity for women to continue to undergo recommended cervical cancer screening.> > > > Recipients of GARDASIL should not discontinue anal cancer screening if it has been recommended by a health care provider.> > > > GARDASIL has not been demonstrated to provide protection against diseases from vaccine and non-vaccine HPV types to which a person has previously been exposed through sexual activity.> > > > GARDASIL is not intended to be used for treatment of active external genital lesions; cervical, vulvar, vaginal, and anal cancers; cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, or anal intraepithelial neoplasia.> > > > GARDASIL has not been demonstrated to protect against disease due to HPV types not contained in the vaccine.> > > > Not all vulvar, vaginal, and anal cancers are caused by HPV, and GARDASIL protects only against those vulvar, vaginal, and anal cancers caused by HPV 16 and 18.> > > > Select safety information> > GARDASIL is contraindicated in individuals with hypersensitivity, including severe allergic reactions to yeast, or after a previous dose of GARDASIL.> > > > Because vaccinees may develop syncope, sometimes resulting in falling with injury, observation for 15 minutes after administration is recommended. Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported following vaccination with GARDASIL. When syncope is associated with tonic-clonic movements, the activity is usually transient and typically responds to restoring cerebral perfusion.> > > > GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] is not recommended for use in pregnant women.> > > > The most common adverse reaction was headache. Common adverse reactions that were observed among recipients of GARDASIL at a frequency of at least 1.0 percent and greater than placebo were: fever, nausea, dizziness; and injection-site pain, swelling, erythema, pruritus and bruising.> > > > Dosage and administration for GARDASIL> > GARDASIL is a ready-to-use, three-dose, intramuscular vaccine. GARDASIL should be administered in three separate intramuscular injections in the deltoid region of the upper arm or in the higher anterolateral area of the thigh. The following dosage schedule is recommended: First dose at elected date, second dose two months after the first dose and the third dose six months after the first dose.> > > > GARDASIL is approved in 121 countries> > GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] (sold in some countries as SILGARD®) has been approved in 121 countries, and additional applications are currently under review with regulatory agencies in many more countries around the world.> >

Posted

I doubt that you can get your insurance to pay since you are older than the age range on the label. Besides, Merck keeps telling us that it will not work for most of us since we have already been exposed to the most cancer producing genotypes.  Unfortunately, HPV genotype tests are only available for research purposes for men(I wish we could have access to it) Although I guess we could order one of these tests approved for women and pay cash for them:

http://www.arhp.org/publications-and-resources/clinical-proceedings/Managing-HPV/DNA-Testing

A study showed that the HPV vaccine may work for some gay men

http://www.aidsmeds.com/articles/hpv_vaccine_men_1667_18835.shtml

I think the total cost  for the 3 shots is close to $400. You can get it at your doctor's office.  I would love to have access to genotype testing to find out if I really would be wasting my money if I were to decide to get the shots. 

Jeff may be able  to expand more on this. 

On Thu, Dec 23, 2010 at 10:15 PM, Jim98122x <jim98122x@...> wrote:

Does anyone know what this means for those of us who are (WAY)over 26, as relates to having insurance pay for it?  I assume that would be considered " off label " --- Would most insurances pay for it, if it hasn't yet technically been demonstrated to be useful for people over the age of 26?  My insurance pays for most vaccinations without a copay, but I expect this might be a reason why they'd not pay for it.  Anyone with any insight about this sort of thing?

>> > > Subject: NATAP: FDA Approves GARDASIL for Anal Cancer

> > > > > > > > Dec. 22, 2010> > US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL®> > US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL®

> > > > GARDASIL now Approved for Prevention of Anal Cancer and AIN> > > > WHITEHOUSE STATION, N.J., Dec. 22, 2010 - Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

> > > > " We are pleased that with this new indication for GARDASIL against HPV-related anal cancer and disease, both males and females can be protected against cancer, which further reinforces the importance of vaccinating both genders, " said M. Haupt, M.D., MPH, executive director, Merck Research Laboratories. " GARDASIL is the only HPV vaccine available for use in both males and females, and the only one indicated to help prevent cervical, vaginal, vulvar and anal cancers and pre-cancers, as well as genital warts, caused by certain types of HPV. "

> > > > In the United States, an estimated 75 to 80 percent of males and females will be infected with HPV in their lifetime. For most, HPV will clear on its own. However, for those who don't clear certain types, HPV can cause cervical, vaginal and vulvar cancers in women and anal cancer and genital warts in men and women. There is no way to predict who will or won't clear the virus.

> > > > GARDASIL helps protect against the four types of HPV, specifically types 6, 11, 16, and 18, that cause the most disease. It is estimated that HPV types 16 and 18 account for approximately 80 percent of anal cancers, 75 percent of cervical cancers, 70 percent of vaginal cancers and 40 to 50 percent of vulvar cancers. HPV types 6 and 11 cause approximately 90 percent of all genital warts cases.

> > > > Anal cancer affects both men and women, with approximately 60 percent of cases occurring in women. According to the American Cancer Society, it is estimated that approximately 2,000 men and more than 3,000 women will have been diagnosed with anal cancer in 2010. There is no standardized screening recommended for the general population for anal cancer and many people are diagnosed when the disease is more advanced.

> > > > GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] was approved in the United States in 2006 and is also indicated for use in girls and young women 9 through 26 years of age for the prevention of cervical, vulvar and vaginal cancers caused by HPV types 16 and 18; genital warts (condylomata acuminata) caused by HPV types 6 and 11; and precancerous or dysplastic lesions caused by HPV types 6, 11, 16 and 18. GARDASIL is also approved in the U.S. for use in boys and men ages 9 through 26 years of age for the prevention of genital warts caused by HPV types 6 and 11.

> > > > Important information about GARDASIL> > GARDASIL does not eliminate the necessity for women to continue to undergo recommended cervical cancer screening.> > > > Recipients of GARDASIL should not discontinue anal cancer screening if it has been recommended by a health care provider.

> > > > GARDASIL has not been demonstrated to provide protection against diseases from vaccine and non-vaccine HPV types to which a person has previously been exposed through sexual activity.> >

> > GARDASIL is not intended to be used for treatment of active external genital lesions; cervical, vulvar, vaginal, and anal cancers; cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, or anal intraepithelial neoplasia.

> > > > GARDASIL has not been demonstrated to protect against disease due to HPV types not contained in the vaccine.> > > > Not all vulvar, vaginal, and anal cancers are caused by HPV, and GARDASIL protects only against those vulvar, vaginal, and anal cancers caused by HPV 16 and 18.

> > > > Select safety information> > GARDASIL is contraindicated in individuals with hypersensitivity, including severe allergic reactions to yeast, or after a previous dose of GARDASIL.> >

> > Because vaccinees may develop syncope, sometimes resulting in falling with injury, observation for 15 minutes after administration is recommended. Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported following vaccination with GARDASIL. When syncope is associated with tonic-clonic movements, the activity is usually transient and typically responds to restoring cerebral perfusion.

> > > > GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] is not recommended for use in pregnant women.> > > > The most common adverse reaction was headache. Common adverse reactions that were observed among recipients of GARDASIL at a frequency of at least 1.0 percent and greater than placebo were: fever, nausea, dizziness; and injection-site pain, swelling, erythema, pruritus and bruising.

> > > > Dosage and administration for GARDASIL> > GARDASIL is a ready-to-use, three-dose, intramuscular vaccine. GARDASIL should be administered in three separate intramuscular injections in the deltoid region of the upper arm or in the higher anterolateral area of the thigh. The following dosage schedule is recommended: First dose at elected date, second dose two months after the first dose and the third dose six months after the first dose.

> > > > GARDASIL is approved in 121 countries> > GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] (sold in some countries as SILGARD®) has been approved in 121 countries, and additional applications are currently under review with regulatory agencies in many more countries around the world.

> >

-- Greetings, VergelAmazon Author profile: http://www.amazon.com/-/e/B003E3RYKY

Posted

I doubt that you can get your insurance to pay since you are older than the age range on the label. Besides, Merck keeps telling us that it will not work for most of us since we have already been exposed to the most cancer producing genotypes.  Unfortunately, HPV genotype tests are only available for research purposes for men(I wish we could have access to it) Although I guess we could order one of these tests approved for women and pay cash for them:

http://www.arhp.org/publications-and-resources/clinical-proceedings/Managing-HPV/DNA-Testing

A study showed that the HPV vaccine may work for some gay men

http://www.aidsmeds.com/articles/hpv_vaccine_men_1667_18835.shtml

I think the total cost  for the 3 shots is close to $400. You can get it at your doctor's office.  I would love to have access to genotype testing to find out if I really would be wasting my money if I were to decide to get the shots. 

Jeff may be able  to expand more on this. 

On Thu, Dec 23, 2010 at 10:15 PM, Jim98122x <jim98122x@...> wrote:

Does anyone know what this means for those of us who are (WAY)over 26, as relates to having insurance pay for it?  I assume that would be considered " off label " --- Would most insurances pay for it, if it hasn't yet technically been demonstrated to be useful for people over the age of 26?  My insurance pays for most vaccinations without a copay, but I expect this might be a reason why they'd not pay for it.  Anyone with any insight about this sort of thing?

>> > > Subject: NATAP: FDA Approves GARDASIL for Anal Cancer

> > > > > > > > Dec. 22, 2010> > US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL®> > US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL®

> > > > GARDASIL now Approved for Prevention of Anal Cancer and AIN> > > > WHITEHOUSE STATION, N.J., Dec. 22, 2010 - Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

> > > > " We are pleased that with this new indication for GARDASIL against HPV-related anal cancer and disease, both males and females can be protected against cancer, which further reinforces the importance of vaccinating both genders, " said M. Haupt, M.D., MPH, executive director, Merck Research Laboratories. " GARDASIL is the only HPV vaccine available for use in both males and females, and the only one indicated to help prevent cervical, vaginal, vulvar and anal cancers and pre-cancers, as well as genital warts, caused by certain types of HPV. "

> > > > In the United States, an estimated 75 to 80 percent of males and females will be infected with HPV in their lifetime. For most, HPV will clear on its own. However, for those who don't clear certain types, HPV can cause cervical, vaginal and vulvar cancers in women and anal cancer and genital warts in men and women. There is no way to predict who will or won't clear the virus.

> > > > GARDASIL helps protect against the four types of HPV, specifically types 6, 11, 16, and 18, that cause the most disease. It is estimated that HPV types 16 and 18 account for approximately 80 percent of anal cancers, 75 percent of cervical cancers, 70 percent of vaginal cancers and 40 to 50 percent of vulvar cancers. HPV types 6 and 11 cause approximately 90 percent of all genital warts cases.

> > > > Anal cancer affects both men and women, with approximately 60 percent of cases occurring in women. According to the American Cancer Society, it is estimated that approximately 2,000 men and more than 3,000 women will have been diagnosed with anal cancer in 2010. There is no standardized screening recommended for the general population for anal cancer and many people are diagnosed when the disease is more advanced.

> > > > GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] was approved in the United States in 2006 and is also indicated for use in girls and young women 9 through 26 years of age for the prevention of cervical, vulvar and vaginal cancers caused by HPV types 16 and 18; genital warts (condylomata acuminata) caused by HPV types 6 and 11; and precancerous or dysplastic lesions caused by HPV types 6, 11, 16 and 18. GARDASIL is also approved in the U.S. for use in boys and men ages 9 through 26 years of age for the prevention of genital warts caused by HPV types 6 and 11.

> > > > Important information about GARDASIL> > GARDASIL does not eliminate the necessity for women to continue to undergo recommended cervical cancer screening.> > > > Recipients of GARDASIL should not discontinue anal cancer screening if it has been recommended by a health care provider.

> > > > GARDASIL has not been demonstrated to provide protection against diseases from vaccine and non-vaccine HPV types to which a person has previously been exposed through sexual activity.> >

> > GARDASIL is not intended to be used for treatment of active external genital lesions; cervical, vulvar, vaginal, and anal cancers; cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, or anal intraepithelial neoplasia.

> > > > GARDASIL has not been demonstrated to protect against disease due to HPV types not contained in the vaccine.> > > > Not all vulvar, vaginal, and anal cancers are caused by HPV, and GARDASIL protects only against those vulvar, vaginal, and anal cancers caused by HPV 16 and 18.

> > > > Select safety information> > GARDASIL is contraindicated in individuals with hypersensitivity, including severe allergic reactions to yeast, or after a previous dose of GARDASIL.> >

> > Because vaccinees may develop syncope, sometimes resulting in falling with injury, observation for 15 minutes after administration is recommended. Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported following vaccination with GARDASIL. When syncope is associated with tonic-clonic movements, the activity is usually transient and typically responds to restoring cerebral perfusion.

> > > > GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] is not recommended for use in pregnant women.> > > > The most common adverse reaction was headache. Common adverse reactions that were observed among recipients of GARDASIL at a frequency of at least 1.0 percent and greater than placebo were: fever, nausea, dizziness; and injection-site pain, swelling, erythema, pruritus and bruising.

> > > > Dosage and administration for GARDASIL> > GARDASIL is a ready-to-use, three-dose, intramuscular vaccine. GARDASIL should be administered in three separate intramuscular injections in the deltoid region of the upper arm or in the higher anterolateral area of the thigh. The following dosage schedule is recommended: First dose at elected date, second dose two months after the first dose and the third dose six months after the first dose.

> > > > GARDASIL is approved in 121 countries> > GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] (sold in some countries as SILGARD®) has been approved in 121 countries, and additional applications are currently under review with regulatory agencies in many more countries around the world.

> >

-- Greetings, VergelAmazon Author profile: http://www.amazon.com/-/e/B003E3RYKY

Posted

It's an interesting conundrum.

HPV genotyping is not available outside of research settings currently.

Planned Parenthood gives the vaccine to girls & women regardless of whether

they've had any abnormal Pap or not. They figure it might protect them, and

insurance pays for it if they're under 26.

As for boys, the CDC still has not changed their recommendation from

'permissive' to 'routine' for boys receiving it, meaning MD's can give it but

it's not considered 'required' and hence insurers are not required to pay for it

for boys. Not yet, anyway.

THis coming spring the CDC's ACIP will meet to decide whether or not to change

the recommendation for boys: and some of us will be there to urge them to do

so.

~

> >

> >

> > > Subject: NATAP: FDA Approves GARDASIL for Anal Cancer

> > >

> > >

> > >

> > > Dec. 22, 2010

> > > US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL®

> > > US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL®

> > >

> > > GARDASIL now Approved for Prevention of Anal Cancer and AIN

> > >

> > > WHITEHOUSE STATION, N.J., Dec. 22, 2010 - Merck, known as MSD

> outside the United States and Canada, announced today that the U.S. Food

> and Drug Administration (FDA) has approved GARDASIL® [Human

> Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine,

> Recombinant] for the prevention of anal cancer caused by human

> papillomavirus (HPV) types 16 and 18 and for the prevention of anal

> intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and

> precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and

> females 9 through 26 years of age.

> > >

> > > " We are pleased that with this new indication for GARDASIL against

> HPV-related anal cancer and disease, both males and females can be

> protected against cancer, which further reinforces the importance of

> vaccinating both genders, " said M. Haupt, M.D., MPH, executive

> director, Merck Research Laboratories. " GARDASIL is the only HPV vaccine

> available for use in both males and females, and the only one indicated

> to help prevent cervical, vaginal, vulvar and anal cancers and

> pre-cancers, as well as genital warts, caused by certain types of HPV. "

> > >

> > > In the United States, an estimated 75 to 80 percent of males and

> females will be infected with HPV in their lifetime. For most, HPV will

> clear on its own. However, for those who don't clear certain types, HPV

> can cause cervical, vaginal and vulvar cancers in women and anal cancer

> and genital warts in men and women. There is no way to predict who will

> or won't clear the virus.

> > >

> > > GARDASIL helps protect against the four types of HPV, specifically

> types 6, 11, 16, and 18, that cause the most disease. It is estimated

> that HPV types 16 and 18 account for approximately 80 percent of anal

> cancers, 75 percent of cervical cancers, 70 percent of vaginal cancers

> and 40 to 50 percent of vulvar cancers. HPV types 6 and 11 cause

> approximately 90 percent of all genital warts cases.

> > >

> > > Anal cancer affects both men and women, with approximately 60

> percent of cases occurring in women. According to the American Cancer

> Society, it is estimated that approximately 2,000 men and more than

> 3,000 women will have been diagnosed with anal cancer in 2010. There is

> no standardized screening recommended for the general population for

> anal cancer and many people are diagnosed when the disease is more

> advanced.

> > >

> > > GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16,

> and 18) Vaccine, Recombinant] was approved in the United States in 2006

> and is also indicated for use in girls and young women 9 through 26

> years of age for the prevention of cervical, vulvar and vaginal cancers

> caused by HPV types 16 and 18; genital warts (condylomata acuminata)

> caused by HPV types 6 and 11; and precancerous or dysplastic lesions

> caused by HPV types 6, 11, 16 and 18. GARDASIL is also approved in the

> U.S. for use in boys and men ages 9 through 26 years of age for the

> prevention of genital warts caused by HPV types 6 and 11.

> > >

> > > Important information about GARDASIL

> > > GARDASIL does not eliminate the necessity for women to continue to

> undergo recommended cervical cancer screening.

> > >

> > > Recipients of GARDASIL should not discontinue anal cancer screening

> if it has been recommended by a health care provider.

> > >

> > > GARDASIL has not been demonstrated to provide protection against

> diseases from vaccine and non-vaccine HPV types to which a person has

> previously been exposed through sexual activity.

> > >

> > > GARDASIL is not intended to be used for treatment of active external

> genital lesions; cervical, vulvar, vaginal, and anal cancers; cervical

> intraepithelial neoplasia, vulvar intraepithelial neoplasia, vaginal

> intraepithelial neoplasia, or anal intraepithelial neoplasia.

> > >

> > > GARDASIL has not been demonstrated to protect against disease due to

> HPV types not contained in the vaccine.

> > >

> > > Not all vulvar, vaginal, and anal cancers are caused by HPV, and

> GARDASIL protects only against those vulvar, vaginal, and anal cancers

> caused by HPV 16 and 18.

> > >

> > > Select safety information

> > > GARDASIL is contraindicated in individuals with hypersensitivity,

> including severe allergic reactions to yeast, or after a previous dose

> of GARDASIL.

> > >

> > > Because vaccinees may develop syncope, sometimes resulting in

> falling with injury, observation for 15 minutes after administration is

> recommended. Syncope, sometimes associated with tonic-clonic movements

> and other seizure-like activity, has been reported following vaccination

> with GARDASIL. When syncope is associated with tonic-clonic movements,

> the activity is usually transient and typically responds to restoring

> cerebral perfusion.

> > >

> > > GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16,

> and 18) Vaccine, Recombinant] is not recommended for use in pregnant

> women.

> > >

> > > The most common adverse reaction was headache. Common adverse

> reactions that were observed among recipients of GARDASIL at a frequency

> of at least 1.0 percent and greater than placebo were: fever, nausea,

> dizziness; and injection-site pain, swelling, erythema, pruritus and

> bruising.

> > >

> > > Dosage and administration for GARDASIL

> > > GARDASIL is a ready-to-use, three-dose, intramuscular vaccine.

> GARDASIL should be administered in three separate intramuscular

> injections in the deltoid region of the upper arm or in the higher

> anterolateral area of the thigh. The following dosage schedule is

> recommended: First dose at elected date, second dose two months after

> the first dose and the third dose six months after the first dose.

> > >

> > > GARDASIL is approved in 121 countries

> > > GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18)

> Vaccine, Recombinant] (sold in some countries as SILGARD®) has been

> approved in 121 countries, and additional applications are currently

> under review with regulatory agencies in many more countries around the

> world.

> > >

>

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...